Emergent BioSolutions has filed a patent for stable pharmaceutical compositions containing an opioid antagonist, isotonicity agent, preservative agent, stabilizing agent, and citric acid. The formulation includes specific concentration ranges for naloxone, NaCl, BZK, EDTA, and citric acid. The patent also covers methods of using these compositions for treatment purposes. GlobalData’s report on Emergent BioSolutions gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Emergent BioSolutions, LPS antibody-based anti-bacterials was a key innovation area identified from patents. Emergent BioSolutions's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
The patent is filed for a stable pharmaceutical composition with naloxone
A recently filed patent (Publication Number: US20230149388A1) describes a formulation for treating opioid exposure. The formulation includes naloxone or a pharmaceutically acceptable salt thereof, NaCl, BZK, EDTA, and citric acid. The concentration of these ingredients varies within specific ranges, such as between 0.3% and 3.0% for naloxone, between 0.3% and 3% for NaCl, between 0.005% and 0.05% for BZK, between 0.02% and 0.25% for EDTA, and between 0.10% and 1.0% for citric acid.
The patent also claims that the formulation can be administered to a subject in need of opioid exposure treatment. The administration can be done through injection, either intramuscularly or subcutaneously, and can be performed using an auto-injector device. The method of treatment involves administering a specific dosage of naloxone from the formulation, which results in various pharmacokinetic parameters such as elimination half-life, AUC in plasma, Cmax, Tmax, and bioavailability falling within certain ranges. The formulation also has specific characteristics, such as osmolality between 250 mOsm and 500 mOsm, and a pH between 3 and 7.
Overall, this patent describes a formulation and method for treating opioid exposure using specific concentrations of naloxone and other ingredients. The formulation can be administered using an auto-injector device and provides desired pharmacokinetic parameters for effective treatment.